Senior Scientific Director, Myeloma Disease Lead
Bristol Myers Squibb (BMS)
Erin Flynt, PhD is currently a Senior Scientific Director at Bristol Myers Squibb (BMS) in the Multiple Myeloma (MM) Group within Translational Medicine. Erin is the MM Disease Lead and is responsible for above-asset disease-oriented TM research. While at Celgene and BMS, Erin has led projects that focused on patient selection, disease biology, and Translational strategy including the Myeloma Genome Project that defined the genomic landscape of newly-diagnosed MM and identified molecularly-defined high-risk patient and disease segments. A similar effort focused on understanding the landscape of relapsed/refractory MM and mechanisms of resistance is ongoing. Erin also leads a multi-institute MM Single-cell Consortium that is investigating the biology of resistant MM at the single-cell level, has supported multiple regulatory submissions and communication for the hematology TM group. Prior to Celgene, Erin supported commercial strategy and medical communications for 9 years for multiple brands and indications where she gained knowledge of clinical practice patterns, the MM treatment landscape, strategy, and communication.